| | | SCIENCE NEWS |
Alnylam Reports Positive Initial Clinical Results for ALN-CC5, an Investigational RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases
Alnylam Pharmaceuticals, Inc. announced initial positive results from its ongoing Phase I/II clinical trial with ALN-CC5, an investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. [Press release from Alnylam Pharmaceuticals, Inc. discussing research presented at the 20th Congress of the European Hematology Association (EHA), Vienna]
Press Release
bluebird bio Reports New Beta-Thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA
bluebird bio, Inc. announced long-term follow up of two patients with beta-thalassemia major and early safety and efficacy data in the first patient with severe sickle cell disease treated with LentiGlobin BB305 product candidate in the HGB-205 study. [Press release from bluebird bio, Inc. discussing research presented at the 20th Congress of the European Hematology Association (EHA), Vienna]
Press Release
NTCELL® Clinical Study in Parkinson’s Meets Endpoints
Living Cell Technologies Limited announced results from a Phase I/IIa clinical study of NTCELL®, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. [Press release from Living Cell Technologies Limited discussing research to be presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego ]
Press Release
From our sponsor: Learn about air-liquid interface culture for respiratory research.
Watch the video.
|
| | | POLICY |
National Library of Medicine Urged to Take on Broader Role
The National Library of Medicine, the world’s largest biomedical library, needs to become the “epicenter for data science” across the National Institutes of Health, an expert panel concluded. But it should continue its current programs, ranging from historical exhibits to training for health librarians. [ScienceInsider]
Editorial
|
Press Release
Russian Researchers Protest Government Reforms
About 3000 Russian scientists rallied in Moscow to protest against government reforms of the research system and the imposition of competitive funding, which is not commonly used in the country. [ScienceInsider] Editorial
|
| | | BUSINESS |
BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform
BIND Therapeutics, Inc. and Macrophage Therapeutics announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables selective, efficient binding to CD206 positive disease-associated macrophages. [BIND Therapeutics, Inc.] Press Release
Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology from Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics, Inc. announced that it has exercised its exclusive option with Memorial Sloan Kettering Cancer Center to license certain clinical stage, allogeneic T-cell therapies for the treatment of cancers and persistent viral infections. [Atara Biotherapeutics, Inc.] Press Release
Cellular Biomedicine Group Enters into Definitive Agreement to Acquire CD40LGVAX Vaccine and Related Technologies and Know-How Which Will Be Used in a Pending PD-1 Combination Clinical Trial in the U.S. for Non-Small Cell Lung Cancer (NSCLC)
Cellular Biomedicine Group Inc. announced that it has entered into a definitive agreement to acquire from Blackbird Bio Finance University of South Florida’s next generation GVAX vaccine’s (CD40LGVAX) related technologies and know-how for an initial consideration of $2.5 million in cash and $1.75 million in shares of the company’s common stock. [Cellular Biomedicine Group Inc.]
Press Release
Sanford Consortium, Takeda Pharmaceutical Partner in $10-Million “Innovation Alliance”
The Sanford Consortium for Regenerative Medicine and the Takeda Pharmaceutical Company Limited have agreed to establish a $10-million, five-year Innovation Alliance that would advance each organization’s research missions. [UC San Diego] Press Release
PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline with License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders
PlasmaTech Biopharmaceuticals, Inc. announced that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline. The company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia disorder and other rare blood diseases. [PlasmaTech Biopharmaceuticals, Inc.]
Press Release
Cord Blood Registry’s New Disease Registry Brings Data & Families Together to Advance Stem Cell Research
Cord Blood Registry® announced the launch of CBR’s Family Health Registry, a unique registry designed to offer insight into common diseases and conditions affecting families and to bring patients, healthcare professionals and researchers together to expedite and facilitate research related to the discovery of stem cell treatments and potential cures. [Cord Blood Registry®]
Press Release
Heat Biologics Announces Development of ComPACT, a Next Generation Combination Immunotherapy Platform
Heat Biologics, Inc. announced the development of its next-generation combination immunotherapy platform, which combines a pan-antigen T cell priming vaccine and T cell co-stimulator in a single product. [Heat Biologics, Inc.] Press Release
STEMCELL Technologies Named Company of the Year by BIOTECanada
STEMCELL Technologies Inc. will be presented with the Biotech Company of the Year award by BIOTECanada at this year’s BIO International Convention in Philadelphia. [BIOTECanada] Press Release
Creighton Researcher Earns NIH Grant to Study Gene, Stem Cell Therapy for Coronary Grafts
A Creighton University researcher has received a National Institutes of Health (NIH) grant to study the effects of gene and stem cell therapy in coronary artery bypass grafts, a first-of-its-kind undertaking that could transform the procedure, increase survival rates and dramatically reduce the possibility of re-occlusion of the grafted arteries and veins in the procedure. [Creighton University]
Press Release
|
|
